RESEARCH ARTICLE
Malignancy-Associated Dyslipidemia
Agata Bielecka-Dąbrowa1, Simon Hannam2, Jacek Rysz3, Maciej Banach1, *
Article Information
Identifiers and Pagination:
Year: 2011Volume: 5
First Page: 35
Last Page: 40
Publisher ID: TOCMJ-5-35
DOI: 10.2174/1874192401105010035
Article History:
Received Date: 1/12/2010Revision Received Date: 5/1/2011
Acceptance Date: 6/1/2011
Electronic publication date: 24/2/2011
Collection year: 2011
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Cholesterol and triglycerides, important lipid constituents of cell, are essential to carry out several vital physiological functions. Lipids might be associated with cancers because they play a key role in the maintenance of cell integrity. The pathway for cholesterol synthesis may also produce various tumorigenic compounds and cholesterol serves as a precursor for the synthesis of many sex hormones linked to increased risk of various cancers. In some malignant diseases, blood cholesterol undergoes early and significant changes. The mechanism for the link between cancer and cholesterol remains controversial. The dates from studies are confusing because both hypolipidemia and hypercholesterolemia might be connected with malignancy. Not only cancers but also antineoplastic therapies have an influence on lipid profile. There are also dates suggesting that antihyperlipemic drugs might nfluenced malignancy.
